News & events

Research and company
updates.

Selected publications, recognition, and conversations across the life sciences community.

October2026

Alyssa Nicholas joins NanomediGene as Investor Relations Lead.

Alyssa Nicholas joins NanomediGene on October 12, 2026, as Investor Relations Lead, supporting investor communications, outreach coordination, and follow-up.

An MBA candidate at Yale School of Management and a two-time healthtech founder, Alyssa brings experience in healthcare consulting, venture capital, and diagnostics.

Meet Alyssa

NanomediGene welcomes Alyssa Nicholas as Investor Relations Lead

October2026Pitch: Oct 22

BIO Alabama 2026 Annual Conference

Selected to pitch
at BIO Alabama 2026.

NanomediGene has been selected to present in the Pitch Program at the BIO Alabama 2026 Annual Conference. Founder and CEO Yasin Oduk, Ph.D., will present on October 22 at Renaissance Ross Bridge Resort & Spa in Hoover (Birmingham area), Alabama, sharing NMG’s metabolic oncology focus and ACC-inhibitor formulation program for breast cancer. The conference takes place October 22–23, 2026.

Official conference details

Yasin Oduk, founder and CEO of NanomediGene, pitching at BIO Alabama on October 22, 2026

September2026Boston, MA

J.P. Morgan Life Sciences & Healthcare Innovator Summit

Joining the biotech conversation
at Harvard Medical School.

NanomediGene founder Yasin Oduk attended the J.P. Morgan Life Sciences & Healthcare Innovator Summit at Harvard Medical School in Boston on September 10, 2026. He joined researchers, founders, and investors for discussions on biotechnology development and company building, and raised a question about financing the early data needed to advance a biotech program.

Read Yasin’s LinkedIn recap

August2026

Shan et al. (2026): ACC inhibition, combinations and resistance.

Shan et al., with Lajos Pusztai as senior author, examine the ACC inhibitor PF-05175157, cellular stress, and potential anticancer combinations in preclinical models. Published in Clinical Cancer Research.

Read our research feature

May2026